Amivantamab Plus Lazertinib Improves PFS Over ...

The MARIPOSA trial showed amivantamab-vmjw plus lazertinib significantly improves progression-free survival over osimertinib in EGFR-mutated NSCLC patients, with a trend toward better overall survival. Safety profiles were consistent with prior data, highlighting the combination's potential as a new standard of care.